Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
You may also be interested in...
Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
Enanta Stumbles In Trying To Show Better FXR Agonist Profile In NASH
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Alios Buy Best Forgotten For Johnson & Johnson As RSV Failure Costs It Dear
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.